SCHEMBL13629298

SCHEMBL13629298

CCc1ccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 1/20 0.49
THRB P10828 1/20 0.49
HTT P42858 1/20 0.49
CYP3A4 P08684 7/20 0.49
CYP2D6 P10635 5/20 0.49
PSEN1 P49768 4/20 0.49
PSEN2 P49810 4/20 0.49
APH1B Q8WW43 4/20 0.49
NCSTN Q92542 4/20 0.49
APH1A Q96BI3 4/20 0.49
PSENEN Q9NZ42 4/20 0.49
HTR6 P50406 2/20 0.48
PGR P06401 1/20 0.48
ACLY P53396 1/20 0.48
PKM P14618 2/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629403 0.89 CES1 (0.58) MEN1ALDH1A1LMNAKMT2AMAPT
SCHEMBL13629418 0.88 PKM (0.61) ALDH1A1LMNAMAPTPGRPKM
SCHEMBL13629553 0.84 PKM (0.56) ALDH1A1LMNAMAPTCYP3A4CYP2D6
SCHEMBL29561406 0.81 MEN1 (0.59) MEN1ALDH1A1LMNAKMT2AMAPT
SCHEMBL13629411 0.80 PPARG (0.55) MEN1ALDH1A1LMNAKMT2AMAPT
SCHEMBL13629296 0.80 ALDH1A1 (0.57) MEN1ALDH1A1LMNAKMT2AMAPT
SCHEMBL13629427 0.79 ALDH1A1 (0.54) MEN1ALDH1A1LMNAKMT2AMAPT
SCHEMBL13615171 0.79 MEN1 (0.48) MEN1ALDH1A1LMNAKMT2AMAPT
SCHEMBL13629417 0.78 KMT2A (0.52) MEN1LMNAKMT2AMAPTNPSR1
SCHEMBL13853000 0.78 KMT2A (0.55) MEN1ALDH1A1LMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK MEN1 1920/4885ALDH1A1 2121/4885LMNA 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.